K. Burock

6.1k total citations
21 papers, 250 citations indexed

About

K. Burock is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, K. Burock has authored 21 papers receiving a total of 250 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 6 papers in Cancer Research and 5 papers in Oncology. Recurrent topics in K. Burock's work include Renal cell carcinoma treatment (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Cancer Genomics and Diagnostics (5 papers). K. Burock is often cited by papers focused on Renal cell carcinoma treatment (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Cancer Genomics and Diagnostics (5 papers). K. Burock collaborates with scholars based in United States, Germany and Taiwan. K. Burock's co-authors include Cezary Szczylik, Ulrich Keilholz, Bernard Escudier, Emilio Bajetta, D. J. Richel, Michael Staehler, U.P. Strauss, Sergio Bracarda, Giuseppe Procopio and Sylvie Négrier and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Journal of Hepatology.

In The Last Decade

K. Burock

20 papers receiving 242 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Burock United States 9 155 136 105 55 23 21 250
Qi Xia United States 9 216 1.4× 206 1.5× 134 1.3× 122 2.2× 23 1.0× 26 418
Tristan Maurina France 10 154 1.0× 118 0.9× 73 0.7× 108 2.0× 18 0.8× 30 293
Jitka Abrahámová Czechia 10 182 1.2× 168 1.2× 91 0.9× 147 2.7× 11 0.5× 44 406
Chirag Amin United States 6 210 1.4× 195 1.4× 123 1.2× 42 0.8× 29 1.3× 17 309
Vincent Verschaeve Belgium 9 147 0.9× 157 1.2× 59 0.6× 112 2.0× 100 4.3× 21 389
María José Méndez-Vidal Spain 13 252 1.6× 139 1.0× 110 1.0× 147 2.7× 10 0.4× 50 410
Annalisa Guida Italy 11 246 1.6× 108 0.8× 72 0.7× 165 3.0× 13 0.6× 39 323
J.-L. Lee South Korea 8 215 1.4× 129 0.9× 91 0.9× 137 2.5× 9 0.4× 11 339
Michela Lia Italy 9 249 1.6× 112 0.8× 70 0.7× 147 2.7× 11 0.5× 15 328
S. T. Kim United States 8 296 1.9× 252 1.9× 190 1.8× 115 2.1× 7 0.3× 16 373

Countries citing papers authored by K. Burock

Since Specialization
Citations

This map shows the geographic impact of K. Burock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Burock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Burock more than expected).

Fields of papers citing papers by K. Burock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Burock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Burock. The network helps show where K. Burock may publish in the future.

Co-authorship network of co-authors of K. Burock

This figure shows the co-authorship network connecting the top 25 collaborators of K. Burock. A scholar is included among the top collaborators of K. Burock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Burock. K. Burock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Locatelli, Franco, Bülent Antmen, Hyoung Jin Kang, et al.. (2024). Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study. The Lancet Haematology. 11(8). e580–e592. 4 indexed citations
3.
Locatelli, Franco, Bülent Antmen, Hyoung Jin Kang, et al.. (2023). S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDY. HemaSphere. 7(S3). e54405ff–e54405ff. 1 indexed citations
4.
Barraco, Fiorenza, Richard Greil, Raoul Herbrecht, et al.. (2020). Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis. British Journal of Haematology. 191(5). 764–774. 22 indexed citations
5.
Sparagana, Steven, David Neal Franz, Darcy A. Krueger, et al.. (2017). Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex. PLoS ONE. 12(10). e0186235–e0186235. 12 indexed citations
6.
7.
Procopio, Giuseppe, Emilio Bajetta, Ulrich Keilholz, et al.. (2011). Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Annals of Oncology. 22(8). 1812–1823. 106 indexed citations
8.
9.
10.
Tak, Won Young, Shaoyong Yu, Shukui Qin, et al.. (2009). 823 IMPACT OF PRIOR TACE/TAE ON THE EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FROM THE ASIA-PACIFIC REGION. Journal of Hepatology. 50. S301–S301. 2 indexed citations
11.
Staehler, Michael, Giuseppe Procopio, Ulrich Keilholz, et al.. (2009). 254 A SUBANALYSIS OF PATIENTS WITH AND WITHOUT PRIOR NEPHRECTOMY IN A LARGE OPEN-LABEL, NON-COMPARATIVE PHASE 3 EUROPEAN ADVANCED RENAL CELL CARCINOMA (RCC) SORAFENIB STUDY (EU-ARCCS). European Urology Supplements. 8(4). 184–184. 2 indexed citations
12.
Beck, J. Thaddeus, et al.. (2009). 7137 Final analysis of a large open-label, noncomparative, phase 3 study of sorafenib in European patients with advanced RCC (EU-ARCCS). European Journal of Cancer Supplements. 7(2). 434–435. 9 indexed citations
13.
Bracarda, Sergio, Giuseppe Procopio, Ulrich Keilholz, et al.. (2009). 142 ELDERLY PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)SUCCESSFULLY TREATED. European Urology Supplements. 8(4). 156–156. 2 indexed citations
14.
Yang, T.-S., Shenghui Qin, Won Young Tak, et al.. (2009). Impact of prior surgical resection with curative intent on the efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Subset analysis of the Asia-Pacific (AP) study. Journal of Clinical Oncology. 27(15_suppl). e15518–e15518. 1 indexed citations
15.
16.
Qin, Shenghui, Won Young Tak, Shaoqing Yu, et al.. (2009). Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Asia-Pacific (AP) trial subgroup analyses by baseline transaminase (ALT/AST)/α-fetoprotein (AFP) levels. Journal of Clinical Oncology. 27(15_suppl). 4590–4590. 1 indexed citations
17.
Beck, J. Thaddeus, Giuseppe Procopio, Elena Verzoni, et al.. (2008). Large open-label, non-comparative, clinical experience trial of the multi-targeted kinase inhibitor sorafenib in European patients with advanced RCC. Journal of Clinical Oncology. 26(15_suppl). 16021–16021. 4 indexed citations
18.
Beck, J. Thaddeus, Elena Verzoni, Ulrich Keilholz, et al.. (2008). A LARGE OPEN-LABEL, NON-COMPARATIVE, PHASE III STUDY OF THE MULTI-TARGETED KINASE INHIBITOR SORAFENIB IN EUROPEAN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA. European Urology Supplements. 7(3). 244–244. 17 indexed citations
19.
Beck, J. Thaddeus, Emilio Bajetta, Bernard Escudier, et al.. (2007). 4506 ORAL A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. European Journal of Cancer Supplements. 5(4). 300–300. 29 indexed citations
20.
Kröger, Nicolaus, Oleg Gluz, Svjetlana Mohrmann, et al.. (2006). Randomized Trial of Single Compared With Tandem High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation in Patients With Chemotherapy-Sensitive Metastatic Breast Cancer. Journal of Clinical Oncology. 24(24). 3919–3926. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qi Xia Breakdown of academic impact, for papers by Tristan Maurina Breakdown of academic impact, for papers by Jitka Abrahámová Breakdown of academic impact, for papers by Chirag Amin Breakdown of academic impact, for papers by Vincent Verschaeve Breakdown of academic impact, for papers by María José Méndez-Vidal Breakdown of academic impact, for papers by Annalisa Guida Breakdown of academic impact, for papers by J.-L. Lee Breakdown of academic impact, for papers by Michela Lia Breakdown of academic impact, for papers by S. T. Kim
Rankless by CCL
2026